{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Phase 3 Study Validates New Biologic With Gut-Specific Directed Activity - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"zdywE9EyT4\"><a href=\"https:\/\/themedicalxchange.com\/en\/2012\/11\/05\/american-college-of-gastroenterology-acg-2012-annu\/\">Phase 3 Study Validates New Biologic With Gut-Specific Directed Activity<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2012\/11\/05\/american-college-of-gastroenterology-acg-2012-annu\/embed\/#?secret=zdywE9EyT4\" width=\"600\" height=\"338\" title=\"&#8220;Phase 3 Study Validates New Biologic With Gut-Specific Directed Activity&#8221; &#8212; The Medical Xchange\" data-secret=\"zdywE9EyT4\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2012\/11\/ACG_7005_Figure_1_EN.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Las Vegas \u2013 A new biologic with a unique target of activity appears to be nearing regulatory approval for the treatment of inflammatory bowel diseases (IBD), according to phase 3 data. The drug, called vedolizumab, targets \u03b14\u03b27 integrin, which specifically mediates lymphocyte trafficking to the gut. In separate phase 3 trials in ulcerative colitis (GEMINI I) and Crohn's disease (GEMINI II), the low rate of infectious complications relative to rates typically encountered with tissue necrosis factor (TNF) inhibitors suggest that the unique mechanism of action may be clinically important in the treatment of IBD."}